tbuckley/cabot-search huggingface dataset:
Immunologic Findings in Kawasaki Disease
Authors: A. DAMIANO
Journal: Annals of Internal Medicine (1981)

Letters1 January 1981Immunologic Findings in Kawasaki DiseaseA. DAMIANO, M.D., D. ZULAICA, M.D., E. CUADRADO, M.D., M. OCHOA, M.D.A. DAMIANO, M.D.Search for more papers by this author, D. ZULAICA, M.D.Search for more papers by this author, E. CUADRADO, M.D.Search for more papers by this author, M. OCHOA, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-1-138_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Recently, a paper in your journal (1) and a symposium (2) have been devoted to Kawasaki disease. In spite of the vast cumulative data, its pathogenesis remains unclear. Screening for viral infections has been unsuccessful, and a hypersensitivity reaction against an unknown antigen is supported by the inconsistant finding of circulating immune complexes (3, 4), decreased serum levels of C3 and C4, and abnormally high values of serum IgE (5). We found an unusual pattern of IgM and C3 deposits in skin biopsy specimens from a patient with Kawasaki disease.A 10-year-old boy was hospitalized with a...References1. MILGROMPALMERSLOVINMORENSFREEDMANVAUGHAN HESDSJ. Kawasaki disease in a healthy young adult. Ann Intern Med. 1980;92:467-70. LinkGoogle Scholar2. Symposium on Kawasaki disease. Japan J Med Sci Biol. 1979;32:236. Google Scholar3. FOSSARDTHOMPSON CR. Mucocutaneous lymph-node syndrome (Kawasaki disease): a probable soluble-complex disorder. Br Med J. 1977;1:883. CrossrefMedlineGoogle Scholar4. WEINDLINGLEVINSKYMARSHALL ARW. Circulating immune complexes in mucocutaneous lymph node syndrome (Kawasaki disease). Arch Dis Child. 1979;54:241. CrossrefMedlineGoogle Scholar5. KUSAKAWAHEINER SD. Elevated levels of immunoglobulin E in the acute febrile mucocutaneous lymph node syndrome. Pediatr Res. 1976;10:108. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Departamento de Medicina Seccion de Inmunologia Residencia Sanitaria Na Sa de Aranzazu Facultad de Medicina de la Universidad del Pais Vasco San Sebastian Spain PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe Effect of Immunoglobulin on Immune Complexes in Patients with Kawasaki Disease (MCLS)Platelet immune complex interaction in pathogenesis of Kawasaki disease and childhood polyarteritis.Complement and protease inhibitors in the mucocutaneous lymph node syndromeNeuromuscular and Immunochemical Abnormalities in an Adult Man with Kawasaki DiseaseJOHN T. HICKS, M.D., ANDRAS KORENYI-BOTH, M.D., PETER D. UTSINGER, M.D., ERNEST M. BARAN, M.D., GEORGE E. McLAUGHLIN, M.D. 1 January 1981Volume 94, Issue 1Page: 138-139KeywordsAntigensBiopsyHypersensitivityImmune complexKawasaki diseasePathogenesis Issue Published: 1 January 1981 PDF downloadLoading ...
Dental health in patients susceptible to infective endocarditis.
Authors: H A Fleming, S W Newsom
Journal: BMJ (1981)

histolytica.3We feel it is important that there should be an awareness of the possibility that amoebiasis may exist in homosexual patients presenting with diarrhoea, since this may be misdiagnosed as inflammatory bowel disease and corticosteroids would be inappropriate in such cases and might result in fulminant amoebic infection.7
Bariatric surgery improved HbA<sub>1c</sub>more than intensive medical therapy in obese patients with uncontrolled type 2 DM
Authors: B. Gisella Carranza Leon, Victor M. Montori
Journal: Annals of Internal Medicine (2014)

Source Citation Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370:2002-13. 24679060
Erythema multiforme, drugs, and ulcerative colitis.
Authors: A. J. Cameron, J. H. Baron, B. L. Priestley
Journal: BMJ (1966)

MEDICAL JOURNALpast history of parental loss, neglect, or cruelty.The escapist alcohol addicts, in contrast, seem often from their own accounts to have been pampered, over-indulged children.Three personality categories were defined, and after clinical assessment on referral each patient was assigned to the one considered most appropriate:1. Impunitive patients were those thought to be hedonists, carefree and uninhibited people, not inclined to blame themselves for failures or misdemeanours.They were low in hostility, and certainly did not turn aggressiveness upon themselves.2. Moderately self-punitive patients were those who expressed remorse for the harm they caused other people, who were self-critical and discussed their failings, and were assessed as low in self-esteem.3. Grossly self-punitive patients were conspicuous for selfreproach and self-disgust.Some referred to themselves as rubbish, devils, monsters, or outcasts.Women placed in this category some- times said they were prostitutes or evil.These harshly self-critical patients often roused much concern and attention in other patients and in treatment staff as a result of their castigation of themselves.TABLE V.-Relation Between Conscience-structure and Outcome After Six Months Impunitive Moderately Grossly Self-punitive Self-punitive Abstinent .. 12 12 0 Relapsing but abstinent 5 12 4Drinking.. 8 15 11 = 13 30; d.f.= 4; P <0 01.Table V shows that the alcoholics who did best in treatment (as judged by their drinking status six months after referral) were the moderately self-critical patients.The next most favourable outcome occurred in the impunitive patients (hedonists).Those who responded least well to treatment, not one of them achieving abstinence, were the patients rated as grossly self-critical. SummaryOver half the alcohol addicts treated in a specialized clinic were found to be abstinent after six months and also after 18 months.Many of these abstinent patients had episodes of drinking, showing that for them outpatient treatment after the initial hospitalization had been necessary.Although few needed readmission, the number requiring outpatient support increased with the length of the follow-up period.* From the Middlesex and Central Middlesex Hospitals, London. Case 1A 42-year-old schoolmistress was admitted to hospital on 2 November 1953 with a nine-weeks history of bloody diarrhoea (5 to 10 motions daily), colicky lower abdominal pain, anorexia, and vomiting.Her previous health had been good apart from asthma during adolescence.She was thin, her temperature was 100.4°F.(38' C.), and lower abdominal tenderness was noted.Sigmoido- scopy showed a granular proctitis.Haemoglobin was 10.2 g./100 ml., W.B.C. 7,600/c.mm., and E.S.R. 50 mm.per hour (Westergren).No pathogens were isolated on stool culture.Changes compatible with mild ulcerative colitis involving the descending and sigmoid colon were seen on barium enema.
Abstract OT3-4-06: Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial
Authors: F-C Bidard, S Baffert, D Hajage, E Brain, S Armanet, C Simondi, L Mignot, B Asselain, P Tresca, J-Y Pierga
Journal: Cancer Research (2012)

Abstract Background: Baseline CTC count already demonstrated its accuracy as an independent prognostic marker in metastatic breast cancer (MBC), before the start of any treatment (Cristofanilli, NEJM 2004; Pierga Ann Oncol 2011) for progression free survival and overall survival. Multivariate analyses performed in both a pooled analysis (Liu, ASCO 2011) and in the IC 2006–04 study showed that the other independent prognostic factors were the performance status and hormone-receptor (HR) status. Oppositely, the other criteria that are frequently used to choose between hormone therapy and chemotherapy for the treatment of first line hormone receptor-positive MBC patients (e.g. number of metastatic sites, visceral disease, metastasis-free interval…) were not independent prognostic factors. As CTC count is highly correlated to PFS, we designed a large pivotal phase III trial to evaluate the use of CTC to determine the disease aggressiveness and the choice of first line treatment in potentially hormonosensitive MBC. Trial design: First line metastatic breast cancer patients will be randomized between the clinician choice and CTC count-driven choice. In the CTC arm, patients with ≥5 CTC/7.5ml will receive chemotherapy whereas patients with &amp;lt;5 CTC/7.5ml will receive endocrine therapy as first line treatment. Eligibility criteria: Main inclusion criteria include hormone receptor-positive metastatic breast cancer patients with no previous treatment for the metastatic disease, and who can receive either hormone therapy or chemotherapy as first line treatment. Statistical methods: As every patient will receive a treatment, this pivotal trial has been designed to show a non-inferiority of the CTC arm for PFS (primary clinical endpoint) and a superiority of the CTC arm for the medico-economics study (co-primary endpoint). Present accrual and target accrual: This trial began in March 2012 and more than 15 French cancer centers participate to this study. The accrual of 996 metastatic breast cancer patients should be completed in 2 to 3 years. 20 patients have been included in 2 months in the first opened center. Contact information for people with a specific interest in the trial The STIC CTC METABREAST trial has been funded by the French Ministry of Health (STIC program) and Veridex. The promoter is the Institut Curie (Paris). Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr OT3-4-06.
Are Evening Surgeries Necessary?
Authors: N. Jones
Journal: BMJ (1964)

MEDICALcertificate on this evidence alone, but this sign of itself indicates a considerable degree of incoordination.One cannot help prejudging the issue as the question invariably arises, " Is this man likely to be found guilty on this evidence ?" The very posing of this question inevitably results in the issue of many more negative certificates than would otherwise be the case.The time has surely come when we must do away with the clinical examination of the accused and substitute a bloodor urinealcohol level above which it would be an offence to be in charge of a motor vehicle.-I am, etc., Swansea, Glam.
New Insights About Vitamin D and Cardiovascular Disease
Authors: Cora McGreevy, David Williams
Journal: Annals of Internal Medicine (2011)

The worsening worldwide trend toward nutritional insufficiency and the emerging knowledge of the nonhormonal actions of vitamin D and its metabolites have increased interest in the synthesis, metabolism, and action of vitamin D. Vitamin D deficiency has been linked with hypertension, myocardial infarction, and stroke, as well as other cardiovascular-related diseases, such as diabetes, congestive heart failure, peripheral vascular disease, atherosclerosis, and endothelial dysfunction. This review discusses the physiology and definition of vitamin D deficiency, evaluates the worldwide prevalence of vitamin D deficiency, and discusses recent evidence for the association between hypovitaminosis D and cardiovascular disease. Few randomized, controlled trials have evaluated the effect of vitamin D replacement on cardiovascular outcomes, and the results have been inconclusive or contradictory. Carefully designed randomized, controlled trials are essential to evaluate the role of vitamin D supplementation in reducing cardiovascular disease.
Blocking angiotensin II receptors with losartan reduces cardiovascular events and stroke
Authors: S. Mayor
Journal: BMJ (2002)

Blocking angiotensin II receptors with losartan significantly reduces the risk of cardiovascular disease and death, as well as reducing the risk of stroke by a quarter, compared with β blockade with atenolol, in patients with hypertension and left ventricular hypertrophy.

These were the key findings from the first major trial to show a difference in cardiovascular outcomes between antihypertensives with different mechanisms of action. The trial's results were reported last week at the annual scientific meeting of the American College of Cardiology in Atlanta.

The …
Human Rights and the Medical Profession
Authors: Farooq A. Padder
Journal: Annals of Internal Medicine (1995)

Letters15 October 1995Human Rights and the Medical ProfessionFarooq A. Padder, MDFarooq A. Padder, MDNassau County Medical Center East; Meadow, NY 11554Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-8-199510150-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The recent article on the prevention of international torture [1] is of extraordinary importance. To arouse public awareness, more needs to be published in the most widely circulated journals. Because most of these crimes occur in countries where most people lack access to the medical journals such as Annals, I suggest that alternative measures be adopted. These could include the creation of help lines, development of closer ties with the medical societies of such countries, publications in the local medical journals, and, perhaps more importantly, increased emphasis on the importance of medical ethics to undergraduate students. Medical ...References1. “American College of Physicians. The role of the physician and the medical profession in the prevention of international torture and in the treatment of its survivors. Ann Intern Med. 1995; 122:607-13.” Google Scholar Author, Article, and Disclosure InformationAffiliations: Nassau County Medical Center East; Meadow, NY 11554 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGraduate public health training in healthcare of refugee asylum seekers and clinical human rights: evaluation of an innovative curriculumSocio-Medical Challenges of Asylum Seekers Prior and After Coming to the USDomestic Global Health: A Curriculum Teaching Medical Students to Evaluate Refugee Asylum Seekers and Torture SurvivorsEthical and Professional Considerations Providing Medical Evaluation and Care to Refugee Asylum SeekersTeaching Residents to Work with Torture Survivors: Experiences from the Bronx Human Rights Clinic 15 October 1995Volume 123, Issue 8Page: 636KeywordsCrimeMedical ethicsUndergraduates Issue Published: 15 October 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract P6-02-03: TGF-b1-inducible protein BIGH3 (transforming growth factor beta-induced gene human clone 3): A new mechanism inducing breast cancer cell apoptosis
Authors: F RezaPoor, R Moritz, CF Phelix, RG LeBaron
Journal: Cancer Research (2013)

Abstract Cancer development and progression is a complex process involving tumor cell mechanisms as well as tumor-host cell interactions. Using autocrine and paracrine mechanisms the cytokine TGF-b1 can influence cancer progression, in part through promoting the synthesis and secretion of extracellular matrix molecules. TGF-β1 strongly upregulates the gene TGFBI, which encodes a secretory protein named BIGH3. BIGH3 is an extracellular matrix, adhesion-class proapoptotic protein characterized by four fasciclin-1 (FAS1)-like domains, a cysteine-rich region and several different integrin-binding sequences. The C-terminus of BIGH3 encodes the integrin-binding peptides EPDIM and RGD. These sequences, and the integrin α3β1, have been implicated as important components of BIGH3-induced apoptosis. Breast cancer cells express the integrin α3β1, which is reported to play various roles including signaling, invasion and metastasis. Breast cancer cells and tumor-host cells express BIGH3 protein, which is expected to accumulate in the presence of TGF-β1. The above findings highlight the molecules TGF-β1 and α3β1 in tumor progression and are the basis for our hypothesis that BIGH3 protein itself is sufficient to induce an increase in breast cancer cell apoptosis. In order to test this hypothesis we utilized human breast cancer MCF-7 cells, human recombinant BIGH3 and TUNEL assays. Here, we show for the first time that exogenous human recombinant BIGH3 in cancer cell growth medium evokes a statistically significant increase in breast cancer cell apoptosis. A concentration curve shows that there is a direct relationship between the quantity of BIGH3 in the cells’ milieu and the number of cells undergoing apoptosis. This finding is consistent with receptor-ligand binding and indicates that BIGH3 is a potential target for breast cancer treatment. Importantly, in-house developed anti-BIGH3 antibody completely blocked apoptosis when compared to apoptotic cells in negative control conditions. Stimulation of BIGH3 gene expression in breast cancer cells, and providing exogenous BIGH3 to breast cancer cells, are expected to diminish breast cancer progression. Along this line, BIGH3 may be valuable as an agent for neoadjuvant or adjuvant therapy for human breast cancer patients. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-02-03.
Reported decline in drug misuse in prison may be illusory
Authors: Owen Dyer
Journal: BMJ (2008)

A substantial reported decline in prison drug misuse in recent years may be illusory: a report has suggested that prisoners may be learning how to cheat the random tests. It also says that such testing in prisons may be driving prisoners towards harder drugs.

Spending on drug treatment in prisons in England and Wales has increased 10 times since 1997, and the proportion of positive results from random mandatory urine tests has fallen by two thirds over the same period, according to Ministry of Justice figures, from 24.4% in 1997 to 8.8% in 2007.

But a report from the Centre for Policy Studies, a conservative leaning think tank founded by Margaret Thatcher, says that this improvement …
Trio receives Lasker Foundation Clinical Award for breakthroughs in leukemia treatment
Authors: Brooke Grindlinger
Journal: Journal of Clinical Investigation (2009)

When Brian J. Druker was a boy, he wanted to be a baseball player; Nicholas B. Lydon had his sights set on flying jets; Charles L. Sawyers knew early on that he wanted to practice medicine. Decades later, this trio (Figure 1) would collaborate to revolutionize the treatment of chronic myelogenous leukemia (CML). On September 14, the Albert and Mary Lasker Foundation announced that they will recognize these researchers with the 2009 Lasker-DeBakey Clinical Medical Research Award for research that led to the development of drugs, including imatinib (Gleevec) and dasatinib (Sprycel), which have converted CML from a fatal cancer to a manageable condition. Notably, imatinib was the first successful, molecularly targeted, small-molecule drug approved for cancer therapy. The winners spoke with the JCI about their success story.
Influence of Anterior Mitral Leaflet Second-Order Chordae Tendineae on Left Ventricular Systolic Function
Authors: Sten Lyager Nielsen, Tomasz A. Timek, G. Randall Green, Paul Dagum, George T. Daughters, J. Michael Hasenkam, Ann F. Bolger, Neil B. Ingels, D. Craig Miller
Journal: Circulation (2003)

Background— The contribution of anterior mitral leaflet second-order (“strut”) chordae tendineae to left ventricular (LV) systolic mechanics is debated; we measured the in vivo contribution of anterior chordae tendineae (ACT) and posterior chordae tendineae (PCT) to regional and global LV contractile function. Methods and Results— Eight sheep had radiopaque markers implanted in the LV epicardium, partitioning the ventricle into 12 regions. Microminiature force transducers and snares were sutured to anterior leaflet “strut” chordae originating from ACT and PCT papillary muscles. Chordal tension, marker images, and hemodynamic data were acquired before and after (CUT) severing ACT and PCT. Fractional area shrinkage and slope of the regional end-diastolic area–regional stroke work relation (r-PRSW) were computed for each LV region. CUT did not affect global LV systolic function but reduced FAS in LV segments near the PCT insertion site: equatorial posterior lateral (19±2% versus 16±2%, P &lt;0.05), apical posterior lateral (23±4% versus 19±4%, P &lt;0.05), and posterior medial LV segments (16±2% versus 13±2%, P &lt;0.05). r-PRSW fell near both the ACT (equatorial anterior medial [84±8 versus 62±11 mm Hg, P &lt;0.05] and lateral [73±7 versus 53±9 mm Hg, P &lt;0.05]) and PCT (apical posterior medial [91±12 versus 67±17 mm Hg, P &lt;0.05] and lateral [72±8 versus 59±9 mm Hg, P &lt;0.05]) LV insertion sites. Maximum tension in PCT was higher than in ACT (0.81±0.1 versus 0.52±0.08 N , P &lt;0.01). Conclusions— Dividing anterior leaflet strut chordae in sheep was associated acutely with regional LV systolic dysfunction near the chordal insertion sites. Caution is necessary when embarking on procedures that cut second-order chordae to treat ischemic mitral regurgitation, since this may compromise LV systolic function in ventricles that are already impaired.
MRC trial of treating hypertension in older adults: Authors' reply
Authors: S. Peart, T W Meade, S J Pocock
Journal: BMJ (1992)

the patients were lost to follow up.This would be unacceptable in any trial in acute myocardial infarction or heart failure, in which I have considerable experience; I cannot understand why a study in hypertension would be different.This loss of patients indicates that the investigators have had serious problems monitoring their patients.Furthermore, it is known that patients lost to follow up differ from patients who remain in trials.Secondly, the number of patient years during which patients received treatment as a proportion of the total number of patient years in the sub- groups was 69% in the diuretic group, 55% in the 3 blocker group, and 69% in the placebo group.Obviously, ifclose to 50% ofthe assigned treatment is not administered it will not be possible to observe any effect.Thirdly, the number of withdrawals from 6 blocker treatment in this single blind study is in contrast to the experience in the Swedish trial in old patients with hypertension (STOP trial)2: 177 patients treated with I6 blockers in the Medical Research Council's trial were withdrawn because of bradycardia compared with none in the STOP trial (B Dahlof, personal communication).Fourthly, the power of the trial was calculated to study active treatment versus placebo.There is clearly insufficient power to permit conclusions regarding lack of effects between the treatment subgroups and placebo group-even more so considering my second point above.Wisely, the STOP trial did not present its subgroup results.None of these important flaws is discussed by the authors.I suggest that the trial should be discussed more in the context of pitfalls and flaws than in the context of treatment of hypertension.
The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies – A multicenter prospective trial
Authors: Jee-Fu Huang, Ming-Lung Yu, Chung-Feng Huang, Chang-Fu Chiu, Chia-Yen Dai, Ching-I. Huang, Ming-Lun Yeh, Jeng-Fu Yang, Ming-Yen Hsieh, Nai-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Liang-Yen Wang, Wan-Long Chuang
Journal: Journal of Hepatology (2010)